Celcuity Inc. (CELC) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 21 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Thu, Aug 13, 2026after close 44 8-K
Q1 FY2026Thu, May 14, 2026after close 44 8-K
Q4 FY2025Wed, Mar 25, 2026after close 84 8-K
Q3 FY2025Wed, Nov 12, 2025after close 43 8-K
Q2 FY2025Thu, Aug 14, 2025after close 45 8-K
Q1 FY2025Wed, May 14, 2025after close 44 8-K
Q4 FY2024Mon, Mar 31, 2025after close 90 8-K

What they guided beta

Q3 FY2026 "The randomized Phase 2 study to evaluate the efficacy and safety of, and determine the recommended Phase 3 dose level of, gedatolisib in combination with darolutamide in patients with prostate cancer is expected to begin in the first half of 2027." exhibit
Q3 FY2026 "We expect that our current cash, cash equivalents and short-term investments will finance our operations through 2029." exhibit
Q2 FY2026 "“We are on track to begin shipping REVTORPYK late in the third quarter of 2026, and we look forward to making this important therapy available to patients with locally advanced or metastatic breast cancer.”" exhibit
Q2 FY2026 "Shipments of REVTORPYK are expected to begin late in the third quarter of 2026." exhibit
Q2 FY2026 "Celcuity expects to provide further updates to results from both the PIK3CA MT and WT cohorts of VIKTORIA-1 at medical conferences in the fourth quarter. 1 st Line Setting Celcuity continues to advance gedatolisib combined with palbociclib and endocrine therapy in the first-line setting for patients with HR+/HER2- ABC through its ongoing Phase 3 VIKTORIA-2 clinical trial." exhibit
Q2 FY2026 "The company expects to provide updated clinical data and additional visibility into its mCRPC development strategy during the fourth quarter of 2026." exhibit
Q2 FY2026 "We expect that our current cash, cash equivalents and short-term investments will finance our operations at least into 2029." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CELC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CELC

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

CELC earnings date badge

HTML

<a href="https://veritasdata.dev/company/CELC/"><img src="https://veritasdata.dev/embed/CELC.svg" alt="CELC earnings date" width="240" height="56"></a>

Markdown

[![CELC earnings date](https://veritasdata.dev/embed/CELC.svg)](https://veritasdata.dev/company/CELC/)

Script

<script async src="https://veritasdata.dev/embed/CELC.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CELC"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.